KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardant Health (GH) Other financing activities (2018 - 2025)

Historic Other financing activities for Guardant Health (GH) over the last 8 years, with Q2 2025 value amounting to $151000.0.

  • Guardant Health's Other financing activities rose 13447.49% to $151000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 270000.0%. This contributed to the annual value of -$153000.0 for FY2024, which is 10072.41% down from last year.
  • Per Guardant Health's latest filing, its Other financing activities stood at $151000.0 for Q2 2025, which was up 13447.49% from $12.1 million recorded in Q1 2025.
  • Guardant Health's Other financing activities' 5-year high stood at $21.3 million during Q2 2023, with a 5-year trough of -$1.7 million in Q4 2021.
  • Moreover, its 5-year median value for Other financing activities was $20500.0 (2022), whereas its average is $2.2 million.
  • Its Other financing activities has fluctuated over the past 5 years, first plummeted by 10205.74% in 2024, then soared by 462295.72% in 2025.
  • Over the past 5 years, Guardant Health's Other financing activities (Quarter) stood at -$1.7 million in 2021, then skyrocketed by 98.95% to -$18000.0 in 2022, then soared by 3727.78% to $653000.0 in 2023, then crashed by 90.96% to $59000.0 in 2024, then soared by 155.93% to $151000.0 in 2025.
  • Its Other financing activities stands at $151000.0 for Q2 2025, versus $12.1 million for Q1 2025 and $59000.0 for Q4 2024.